MEDB-79. MYC-driven upregulation of thede novo serine and glycine pathway is a novel therapeutic target for Group 3 MYC-amplified Medulloblastoma

Despite advances in the molecular sub-classification and risk-stratification of medulloblastoma (MB), a subset of tumours remain refractory to current multimodal therapies. Group 3 (MB(Group3)) patients represent around 25% of MBs, and amplification and elevated expression of MYC in this group corre...

Descripción completa

Detalles Bibliográficos
Autores principales: Adiamah, Magretta, Lindsey, Janet C, Burté, Florence, Kohe, Sarah, Morcavallo, Alaide, Blair, Helen, Hill, Rebecca M, Singh, Mankaran, Crosier, Stephen, Zhang, Tong, Maddocks, Oliver, Peet, Andrew, Chesler, Louis, Hickson, Ian, Maxwell, Ross, Clifford, Steven C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Medulloblastoma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164881/
http://dx.doi.org/10.1093/neuonc/noac079.453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164881/
http://dx.doi.org/10.1093/neuonc/noac079.453

Ejemplares similares